Lori A Charie

Title: Lori A Charie: Innovator in Monoclonal Antibody Development

Introduction

Lori A Charie is a notable inventor based in Hollywood, FL (US). She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work has implications for the detection of various viruses, showcasing her expertise and dedication to scientific advancement.

Latest Patents

Lori A Charie holds a patent for a monoclonal antibody designed for detecting HTLV-I, HTLV-II, and STLV-I viruses. This innovative hybrid cell line is capable of producing monoclonal antibodies that bind to the core antigens p24 and p53 of HTLV-I and HTLV-II, while not binding to the p19 core antigen. Additionally, the antibody is effective against core antigens of simian T-cell leukemia virus Type I (STLV-I). The monoclonal antibody is identified as the KC-88 monoclonal antibody, and the cell line producing it has been deposited in the American Type Culture Collection, Rockville, MD, with the assigned A.T.C.C. Deposit No. HB 10562.

Career Highlights

Lori A Charie is associated with Coulter Corporation, where she has contributed her expertise in antibody development. Her work has been instrumental in advancing the understanding and detection of viral infections, which is crucial for public health.

Collaborations

Lori has collaborated with notable colleagues, including David E Hofheinz and Gary P Toedter. These partnerships have enhanced her research and contributed to the successful development of her patented technologies.

Conclusion

Lori A Charie's innovative work in monoclonal antibody development has made a significant impact in the field of biotechnology. Her contributions continue to advance the detection of important viruses, showcasing her role as a leading inventor in this area.